The twelve hallmarks of aging are the biological framework underlying every intervention in the longevity pharmacopeia. What each hallmark is, why it matters clinically, and which interventions target it.
Longevity medicine without a mechanistic framework is just polypharmacy with optimistic intentions.
The hallmarks of aging — first proposed by López-Otín et al. in Cell in 2013 and updated to twelve hallmarks in 2023 — provide that framework. They are the cellular and molecular processes that accumulate with age, drive age-related disease, and are causally implicated in the aging phenotype. Every intervention in the longevity pharmacopeia targets one or more of these hallmarks.
Understanding which hallmark an intervention targets, and how strong the evidence is that targeting that hallmark translates to clinical benefit, is the foundation of evidence-based longevity medicine. This reference summarizes each hallmark with its clinical relevance and the interventions currently targeting it.
Accumulation of DNA damage over time from endogenous sources (reactive oxygen species, replication errors) and exogenous sources (radiation, toxins). DNA damage activates repair pathways; when repair is overwhelmed, cells undergo senescence or apoptosis. Chronic low-level genomic instability drives aging phenotypes across tissues.
Telomeres — protective caps on chromosomes — shorten with each cell division. When telomeres reach a critical length, cells enter replicative senescence. Telomere length is associated with biological age and age-related disease risk in observational studies, though causal evidence in humans is limited.
Changes in DNA methylation, histone modification, and chromatin remodeling accumulate with age. Epigenetic clocks — algorithms trained on methylation patterns — are among the most accurate biological age estimators available. Epigenetic age acceleration is associated with increased mortality and disease risk.
The proteostasis network — chaperones, the ubiquitin-proteasome system, and autophagy — maintains protein quality by folding, repairing, and degrading damaged proteins. With age, this network declines, leading to accumulation of misfolded and aggregated proteins. Protein aggregation underlies Alzheimer's, Parkinson's, and other age-related neurodegenerative diseases.
Autophagy — the cellular recycling process that degrades damaged organelles and protein aggregates — declines with age. Impaired autophagy accelerates aging phenotypes in animal models; enhanced autophagy extends lifespan in multiple model organisms. Added as a distinct hallmark in the 2023 update.
The nutrient-sensing network — including mTOR, AMPK, insulin/IGF-1 signaling, and sirtuins — coordinates cellular responses to nutrient availability. Chronic overactivation of growth-promoting pathways (mTOR, IGF-1) and underactivation of stress-response pathways (AMPK, sirtuins) drive aging. This hallmark is the mechanistic target of the most evidence-rich longevity interventions.
Mitochondrial function declines with age — reduced ATP production, increased reactive oxygen species generation, and impaired mitochondrial quality control. Mitochondrial dysfunction is implicated in sarcopenia, neurodegeneration, and cardiovascular aging. Mitochondrial biogenesis, regulated partly by PGC-1α, declines with age.
Senescent cells — cells that have permanently exited the cell cycle following stress or damage — accumulate with age. They secrete a pro-inflammatory cocktail (the SASP, senescence-associated secretory phenotype) that drives tissue dysfunction and chronic inflammation. Selective elimination of senescent cells extends healthspan in mouse models.
Adult stem cell populations decline in number and function with age, impairing tissue regeneration and repair. Stem cell exhaustion is particularly relevant in the hematopoietic system, skeletal muscle, and the intestinal epithelium. mTORC1 activation accelerates stem cell exhaustion — providing a mechanistic link to rapamycin's longevity effects.
Age-related changes in cell-to-cell signaling — including increased inflammatory cytokines, altered hormonal signaling, and changes in extracellular vesicle composition — drive systemic aging phenotypes. Chronic low-grade inflammation (inflammaging) is a central feature of this hallmark and a driver of most age-related diseases.
Added as a distinct hallmark in 2023. Chronic low-grade sterile inflammation — not driven by infection — accumulates with age and drives cardiovascular disease, neurodegeneration, metabolic dysfunction, and cancer. Distinct from the acute inflammatory response, inflammaging persists at a smoldering level that causes cumulative tissue damage.
Added as a distinct hallmark in 2023. The gut microbiome changes with age — reduced diversity, increased pathobiont abundance, and altered metabolite production. Gut dysbiosis contributes to systemic inflammation, metabolic dysfunction, and potentially neurodegeneration via the gut-brain axis. The causal direction and clinical significance of age-related dysbiosis remains under active investigation.
The hallmarks provide a framework for understanding why certain interventions are more scientifically credible than others. Rapamycin targets multiple hallmarks through mTORC1 inhibition — proteostasis, autophagy, senescence, stem cell exhaustion, nutrient sensing — which explains why it has the most robust animal lifespan data of any known compound. Metformin and GLP-1 agonists address nutrient sensing and inflammation, which are among the most clinically tractable hallmarks.
What the hallmarks framework also reveals is how much remains unknown. Several hallmarks — telomere attrition, stem cell exhaustion, dysbiosis — have no pharmacological intervention with meaningful human clinical trial data. The gap between mechanistic understanding and clinical evidence is the defining challenge of longevity medicine in 2026.